<DOC>
	<DOCNO>NCT00687440</DOCNO>
	<brief_summary>The purpose study evaluate , first stage , safety ( incidence cardiac toxicity ) Caelyx combination Trastuzumab Docetaxel ; second stage , tumor response rate regimen . This study conduct approximately 30 center . A total approximately 70 95 subject enrol .</brief_summary>
	<brief_title>A Study Determine Activity Caelyx With Trastuzumab Docetaxel Treatment Metastatic Breast Cancer ( Study P03679 )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Patients must fulfill follow criterion : Females age 18 70 yearsold . Willingness participate study comply procedure . Documented diagnosis metastatic breast carcinoma ( stage IV ) Human Epidermal Growth Factor Receptor 2 ( HER2 ) overexpressing ( Immunohistochemistry ( IHC ) 3+ Fluorescence In Situ Hybridization ( FISH ) + ) . No prior chemotherapy metastatic breast cancer . Adjuvant neoadjuvant chemotherapy allow accord follow rule : patient treat anthracyclines follow condition meet : Doxorubicin total dose &lt; = 300 mg/m^2 Epirubicin total dose &lt; = 480 mg/m^2 Chemotherapyfree interval &gt; 12 month taxanebased adjuvant neoadjuvant chemotherapy allow ; patient treat nonanthracycline/taxane adjuvant neoadjuvant chemotherapy regimens freely eligible ( i.e . cyclophosphamide/methotrexate/fluorouracil ( CMF ) similar regimen ) . At least one measurable lesion accord RECIST criterion . Complete hematologic biologic baseline evaluation within 2 week prior start treatment . Complete Tumor baseline evaluation include total body compute tomography ( CT ) scan within 4 week prior start treatment . Left ventricular ejection fraction ( LVEF ) &gt; = 50 % determine echocardiogram Multi Gated Acquisition ( MUGA ) scan . World Health Organization ( WHO ) performance status 0,1 . Life expectancy &gt; 3 month . Laboratory requirement : Hematology : Neutrophils &gt; 1.5 x 10^9/L Platelets &gt; 100 x 10^9/L Hemoglobin &gt; 10 g/dL Hepatic function : Total bilirubin &lt; = 1.25 x uppernormal limit ( UNL ) ; ASAT ( Aspartate Aminotransferase SGOT ) , ALAT ( Alanine aminotransferase SGPT ) &lt; = 2.5 x uppernormal limit ; For patient liver metastasis : Total bilirubin &lt; 1.5 x UNL ( Upper limit normal ) ; ASAT and/or ALAT &lt; 3 x UNL ; Renal function : Serum Creatinine &lt; 1.5 x UNL . Women child bear potential must negative serum pregnancy test use adequate contraception . Patients must accessible treatment followup . Patients enrol follow criterion apply : Prior chemotherapy metastatic disease . History prior malignancy last 10 year ( non melanoma skin cancer excise cervical carcinoma situ ) . Radiation disease area within 3 week study initiation . Symptomatic peripheral neuropathy &gt; grade 2 accord National Cancer Institute ( NCI ) Common Toxicity Criteria . Other serious illness medical condition . LVEF &lt; 50 % determine echocardiogram MUGA scan . Congestive hearth failure angina pectoris even medically control . Previous history myocardial infarction within 1 year study entry , uncontrolled high risk hypertension arrhythmia . History significant neurologic psychiatric disorder include dementia seizure . Active infection . Active peptic ulcer , unstable diabetes mellitus contraindication use dexamethasone . Concurrent treatment experimental drug . Participation another clinical trial investigational drug within 30 day prior study screen . Concurrent treatment corticosteroid use reason premedication . However patient receive chronic treatment corticosteroid ( &gt; 6 month ) low dose ( &lt; 20 mg methylprednisolone equivalent dose corticosteroid ) whichever reason eligible . Taxanebased adjuvant neoadjuvant chemotherapy &lt; 12 month . Other concurrent chemotherapy , immunotherapy , radiotherapy investigational medication , treatment tumor . Pregnant breastfeed woman .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>